SYS-CON MEDIA Authors: PR.com Newswire, RealWire News Distribution, Scott Kinka, Kevin Benedict, Gilad Parann-Nissany

News Feed Item

Global Radiopharmaceuticals Market Report 2013 - 2018

DUBLIN, January 3, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/2q5v4f/radiopharmaceutica) has announced the addition of the "Global Radiopharmaceuticals Market Report 2013 - 2018" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


Radiopharmaceuticals are majorly used to diagnose cancer, tumors, biliary tract blockage, bone diseases, bone marrow diseases, brain diseases, colorectal disease, disorders of iron metabolism and absorption, heart disease, heart muscle damage (infarct), impaired flow of cerebrospinal fluid in the brain, kidney diseases, liver diseases, lung diseases, parathyroid diseases, parathyroid cancer, pernicious anemia, improper absorption of vitamin B12 from intestines, red blood cell diseases, salivary gland diseases, spleen diseases, stomach and intestinal bleeding, stomach problems, tear duct blockage, thyroid diseases, thyroid cancer and urinary bladder diseases.

This may be given to the patient in a number of ways, for e.g. they may be given through the mouth, through injections or placed into the eye or into the bladder. It is a small treatment, which includes use of simple substances containing radioactive isotopes. While treating cancer, these radioactive agents are taken up in the cancerous area to destroy the affected tissues. It works effectively by targeting the areas in the body where the cancer is present. Individuals are suggested to intake radiopharmaceuticals only under the direct supervision of a doctor.

This report analyses the global scenario of the radiopharmaceuticals market, discussing detailed overview and market figures. The research report analyses the industry growth rate, industry capacity, and industry structure. The report analyses the historical data, and forecasts the radiopharmaceuticals market size, production forecasts along with key factors driving and restraining the market.

The report also analyzes the radiopharmaceuticals market by generators and by further classifying them in terms of medical isotopes, their applications, end users and geographic distribution. The medical isotopes category covers major isotopes used in SPECT and PET imaging like technetium, thallium, gallium, rhenium, yttrium and others. The applications market is further classified into diagnosis and therapy. The end user analysis is done by bifurcation of the market into hospitals and outpatient diagnostic centers.

The geography market has been segmented into four major regions - North America, Europe, Asia-Pacific and Rest of the World (RoW). Some of the top radiopharmaceutical companies in the healthcare market are Covidien Plc, Nordion Inc., Lantheus Medical Imaging, IBA Group, Positron Corporation, Cardinal Health, Eckert & Ziegler among others.


Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Executive Summary

Chapter 3 Global Radiopharmaceuticals Market Overview

Chapter 4 Market Definition & Supply Chain Analysis

Chapter 5 Global Radiopharmaceutical Generators Market

Chapter 6 Global Radiopharmaceuticals Market, By End-User Groups

Chapter 7 Global Radiopharmaceuticals Market, By Applications

Chapter 8 Global Radiopharmaceuticals Market, By Geography

Chapter 9 Market Share Analysis By Key Players

Chapter 10 Recommendations

Chapter 11 Company Profiles


Companies Mentioned:

  • Cardinal Health Inc.
  • Covidien Plc
  • GE Healthcare
  • IBA Group
  • Lantheus Medical Imaging
  • Monrol Nuclear Products, Inc.
  • Nordion, Inc.
  • NTP Radioisotopes (Pty) Ltd
  • Polatom
  • Positron Corporation
  • Siemens Healthcare


For more information visit http://www.researchandmarkets.com/research/2q5v4f/radiopharmaceutica


Media Contact: Laura Wood , +353-1-481-1716, [email protected]


SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.